<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00717951</url>
  </required_header>
  <id_info>
    <org_study_id>TAX625</org_study_id>
    <secondary_id>CBCSG003</secondary_id>
    <nct_id>NCT00717951</nct_id>
  </id_info>
  <brief_title>A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer</brief_title>
  <official_title>A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academy Military Medical Science, China</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academy Military Medical Science, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Docetaxol plus capecitabine regimen is the standard treatment for the
      anthracycline-pretreated patients with advanced breast cancer. Cisplatin is an important drug
      for advanced breast cancer and potential effective drug for triple negative breast cancer.The
      study primary objective:Assess ORR,TTP,TTF and 2 year PFS rate between docetaxol+capecitabine
      and docetaxol+cisplatin.

      The second objective:Assess the safety and QOL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study main inclusion criteria are:1.age≥18,KPS&gt;70.2.anthracycline-pretreated patients
      with advanced breast cancer.3.at least 1 measurable lesion as defined by modified RECIST
      criteria.4.screening laboratory values within the following parameters:ANC
      ≥1.5×109/L,Hemoglobin≥10.0 g/dl，Platelet≥100×109/L. 5. signed ICF The patients will be
      randomised two group: docetaxol+capecitabine and docetaxol+cisplatin. According to AE, the
      dose will be adjusted.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR,TTP,TTF and 2 year PFS</measure>
    <time_frame>2008-2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and QOL</measure>
    <time_frame>2008-2010</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A is &quot;docetaxol+capecitabine&quot; chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B is &quot;docetaxol+cisplatin&quot; chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxol, cisplatin, capecitabine</intervention_name>
    <description>docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age≥18y

          -  KPS≥ 70

          -  pathologic diagnosis of breast cancer

          -  at least 1 measurable lesion as defined by modified RECIST criteria

          -  screening laboratory values with the following parameters: hemoglobin:≥10.0 g/dl
             absolute neutrophils count:≥1.5×109/L platelet:≥100×109/L creatinine clearance rate:
             ≥60ml/min total bilirubin: ≤1.5 ×upper limits of normal Alkaline phosphatase,Aspartate
             aminotransferase and Alanine aminotransferase:≤ 2.5×upper limits of normal（≤5×upper
             limits of normal if liver metastasis are present)

          -  signed ICF

          -  for women of child bearing potential,a negative serum or urine pregnancy test result
             before study entry.

        Exclusion Criteria:

          -  More than 2 cytotoxic chemotherapy treatment regimens for metastatic disease.

          -  prior exposure to 5-Fluorouracil continuous infusion.

          -  prior exposure docetaxol for metastatic disease

          -  Any other cancer within 5 years prior to screening with the exception of contralateral
             breast cancer,adequately treated cervical carcinoma in situ,or adequately treated
             basal or squamous cell carcinoma of skin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jiang zefei, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academy MMS,China</affiliation>
  </overall_official>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2008</study_first_submitted>
  <study_first_submitted_qc>July 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2008</study_first_posted>
  <last_update_submitted>July 24, 2008</last_update_submitted>
  <last_update_submitted_qc>July 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Zefei Jiang, Binghe,Xu</name_title>
    <organization>Academy Millitary Medical Science, China</organization>
  </responsible_party>
  <keyword>advanced breast cancer</keyword>
  <keyword>docetaxol</keyword>
  <keyword>capecitabine</keyword>
  <keyword>cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

